Quality of life in diabetic and non diabetic patients on hemodialysis therapy

Abstract

Chronic kidney disease is a worldwide public health problem and a chronic disease that deteriorates the quality of life (QOL). Diabetes is recognized as co-morbidity in patients of end stage renal disease (ESRD). This study evaluated QOL in diabetic and non-diabetic patients on maintenance dialysis therapy. A cross-sectional study was conducted on ESRD with or without diabetes on hemodialysis therapy for at least three months at Kidney Center, Sheikh Zayed Medical Complex, Lahore Pakistan. QOL was assessed using WHOQOL-BREF questionnaire by World Health Organization. One hundred and thirty seven (n=137) hemodialysis patients were observed. 59 (41.8%) were with diabetes mellitus (DM) and 78 (55%) were without DM. 81 (54%) were on hemodialysis for more than 2 years. There was no statistically significant (p≥0.066) difference in QOL scores of hemodialysis patients with or without diabetes; however, a significant (p≤0.025) difference was observed in responses of 'meaningfulness' and "ability to concentrate" by patients of both groups. The scores were divided in two categories of '≤50' and '>50'; a significant (p≤0.047) difference between two groups was observed in physical domain only. The current study on diabetic and non-diabetic hemodialysis patients showed no statistical difference in their QOL except for "meaningfulness of life" and "ability to concentrate".

Additional cost of end-stage kidney disease in diabetic patients according to renal replacement therapy modality: a systematic review

“…Diabetes mellitus (DM) is recognized as the primary cause of ESKD in the USA, Europe, and other regions of the world, with a prevalence ranging between 23 and 39% in ESKD patients [1,12,13]. Diabetic patients on HD have a poorer quality of life, an increased risk of developing/worsening of cardiovascular disease, neurological diseases, and an increased mortality [14][15][16]. As the prevalence of diabetes is increasing worldwide [17], it is expected that a greater number of patients will develop diabetic chronic kidney disease and eventually ESKD [18].…”